Testosterone Enanthate Cost in Arizona (2026): Cash Prices, Insurance, and Savings Options

Testosterone enanthate is a long-acting injectable ester of testosterone, FDA-approved (brand name Delatestryl, plus generic versions from manufacturers such as Perrigo and Hikma) for testosterone replacement in men with hypogonadism. It is a Schedule III controlled substance under the federal Controlled Substances Act. It is distinct from testosterone undecanoate (Aveed) and from the subcutaneous autoinjector Xyosted, which is also a testosterone enanthate formulation but priced and marketed differently. This article is about the intramuscular enanthate ester most commonly dispensed in Arizona pharmacies.

The direct answer: what stays true regardless of the month you read this is that testosterone enanthate is FDA-approved for male hypogonadism, requires a prescription and lab-confirmed diagnosis, and carries a hematocrit-monitoring requirement under Endocrine Society guidance. What does not stay true for long is any specific dollar figure, insurer rule, or Medicaid policy, because pharmacy cash prices, discount-card rates, and state Medicaid formularies change without notice and are not published in a way a general medical reference can verify at scale. Treat every price and coverage rule below as something to reconfirm at the point of purchase, not as a fixed 2026 fact.

What this page can and cannot tell you about price

Cash prices for generic injectable drugs like testosterone enanthate vary by pharmacy, discount-card network, and week. Public price-comparison tools (GoodRx, SingleCare, RxSaver, and individual pharmacy quotes) are the only reliable way to get a current Arizona number, because pricing is set at the pharmacy and PBM level, not by the manufacturer or the state. Any single "average monthly cash price" quoted in an article like this one is a snapshot that can already be stale by the time you read it, and a prior version of this page stated specific dollar averages without a verifiable Arizona-specific source. We are removing those unverified numbers rather than restate them as fact.

What is safe to say in general terms:

• Generic injectable testosterone enanthate is typically far cheaper than the manufacturer's list price once pharmacy discounts, PBM contracts, or cash-discount cards are applied. This is a general pharmacy-economics pattern, not an Arizona-specific data point.
• Compounded testosterone enanthate from a 503A pharmacy is priced independently by each compounding pharmacy and is not required to match commercial generic pricing in either direction.
• Multi-dose vials (10 mL) generally cost less per dose than single-use 1 mL vials, because the fixed dispensing and packaging cost is spread across more doses. This is a general pharmacy math point, not a claim about any specific Arizona price.

If you need an actual number today, call two or three Arizona pharmacies (a chain and an independent) and check a discount-card app directly. That is more reliable than any number printed here.

Does Arizona Medicaid (AHCCCS) cover testosterone enanthate?

State Medicaid programs, including AHCCCS, set their own formularies and can exclude or restrict androgen therapy for adult male hypogonadism. Coverage decisions are made and updated by AHCCCS and its contracted managed care plans (Mercy Care, Banner University Family Care, Arizona Complete Health), and formulary status can change between review cycles. If you rely on AHCCCS, confirm current formulary status directly with AHCCCS or your specific managed care plan rather than relying on any article's stated coverage rule, since we do not have a verified, dated AHCCCS formulary citation to support a specific coverage claim for 2026.

If testosterone enanthate is excluded from your plan's formulary, ask your prescriber's office about the prior authorization appeal process. We do not have a verified success-rate figure for such appeals and are not going to restate an unsupported percentage. The appeal pathway exists procedurally in most Medicaid programs, but whether it succeeds in a given case depends on documentation and the plan's specific criteria.

Does commercial insurance cover it, and what does prior authorization usually require?

Commercial insurers commonly require documentation before authorizing testosterone therapy: two morning total testosterone levels below the lab's reference threshold for hypogonadism (commonly cited around 300 ng/dL in clinical guidance), symptoms consistent with hypogonadism, and a workup ruling out other causes of low testosterone. This pattern is consistent with the general approach described in Endocrine Society clinical practice guidance for testosterone therapy in men with hypogonadism (Bhasin et al., J Clin Endocrinol Metab, 2018). We are not attaching a specific insurer's copay tier or dollar copay range here because those figures are plan-specific, change yearly, and were not independently verified for Arizona plans in this draft; ask your plan or check your Evidence of Coverage document for the current tier and copay.

High-deductible health plans generally pay the pharmacy's contracted cash-equivalent rate until the deductible is met, after which the plan's generic-tier copay applies. Self-funded employer plans (common among large Arizona employers) can set their own pharmacy benefit rules independent of a standard commercial formulary, so a formulary lookup through the insurer's public tool may not reflect your actual plan.

Is compounded testosterone enanthate legal in Arizona, and how is it different?

Yes. Licensed 503A compounding pharmacies may prepare patient-specific testosterone enanthate under a valid prescription, consistent with the federal framework the FDA describes for compounding versus FDA-approved manufacturing (FDA, "Compounding and the FDA: Questions and Answers," https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers). A 503A pharmacy compounds for an individual patient; a 503B outsourcing facility can produce in batches without a patient-specific prescription. Compounded testosterone enanthate is not FDA-approved in the way that the commercially manufactured generic or brand product is, even though the compounding activity itself is legal when done under the applicable rules. That distinction matters for patients weighing customization (non-standard concentration, alternative carrier oil) against the manufacturing oversight that comes with an FDA-approved product. Compounded-product pricing is set independently by each pharmacy and is not tracked in a standardized public database, so any specific dollar figure needs direct confirmation from the pharmacy.

Can you get a prescription through telehealth in Arizona?

Telehealth prescribing of controlled substances, including Schedule III testosterone enanthate, is generally permitted when federal requirements for a valid prescriber-patient relationship are met and state telehealth rules are followed. Because federal telehealth-prescribing flexibilities for controlled substances have been extended and modified multiple times in recent years, confirm the current federal and Arizona-specific rule at the time of your visit rather than assuming a permanent rule, since regulatory status here is date-sensitive.

If you do get a prescription through telehealth, standard practice still requires baseline labs (testosterone, hematocrit, and typically a metabolic panel and PSA in appropriate patients) and follow-up monitoring, described below.

Monitoring is not optional, and it has its own cost

The Endocrine Society's 2018 guideline recommends checking testosterone and hematocrit at approximately 3 months, 6 months, and then annually during testosterone therapy, and stopping or adjusting therapy if hematocrit rises to an unsafe level (Bhasin et al., J Clin Endocrinol Metab, 2018, https://academic.oup.com/jcem/article/103/5/1715/4939465). Elevated hematocrit (erythrocytosis) is a recognized risk of testosterone therapy and is the main reason routine blood count monitoring is built into every reputable prescribing protocol, whether the prescriber is a local endocrinologist, urologist, or a telehealth platform. This monitoring requirement is a clinical fact, independent of where in Arizona you fill the prescription or what it costs.

Total cost of therapy includes the medication, periodic labs, and follow-up visits. Insured patients may pay little for labs coded as diagnostic; uninsured patients should ask their lab or clinic for a self-pay panel price before assuming a specific dollar figure, since we do not have a verified, current Arizona lab-pricing source to cite here.

What the trial evidence actually supports, and its limits

Two trials are frequently cited in testosterone therapy discussions and are relevant to background context, though the specific patient population and outcomes should be checked against the primary paper before being applied to an individual's decision:

• A National Institute on Aging-funded set of placebo-controlled trials in older men with low testosterone and symptoms (widely known as the T-Trials, published in the New England Journal of Medicine in 2016) reported improvements in sexual function and some measures of physical function and mood over about a year of treatment. The trials used transdermal gel, not the injectable enanthate ester, so pharmacokinetic details differ even though both deliver testosterone.
• A large cardiovascular-safety trial in middle-aged and older men with hypogonadism and elevated cardiovascular risk (TRAVERSE, published in the New England Journal of Medicine in 2023) did not find an increased rate of major adverse cardiovascular events with testosterone therapy compared with placebo over the trial's follow-up period. This was reassuring for a question that had been unresolved for years, but it does not establish long-term safety beyond the trial's duration or in populations outside its enrollment criteria.

Neither trial specifically evaluated Arizona patients, cost, or access, and neither is a substitute for an individualized risk discussion with a prescriber, particularly for patients with a history of prostate cancer, uncontrolled heart failure, untreated severe sleep apnea, or elevated hematocrit, all of which are recognized contraindications or cautions for testosterone therapy.

When to involve your prescriber or seek urgent care

Contact your prescriber, do not wait for a routine follow-up, if you notice: new or worsening swelling in the legs, shortness of breath, chest pain, a hematocrit result flagged as high, a new lump in the breast tissue, or urinary symptoms suggestive of prostate enlargement. Chest pain, difficulty breathing, or symptoms of a blood clot (leg swelling with pain and warmth) warrant emergency evaluation, not a wait-and-see approach, regardless of what stage of a cost or coverage decision you are in.

Verification checklist: stable facts versus facts you must re-check

Use this before making a purchasing or coverage decision. The left column rarely changes; the right column can change monthly or by pharmacy and should be re-verified at the point of care.

Stable, federal or clinical (safe to rely on without re-checking monthly)

• Testosterone enanthate is a Schedule III controlled substance under federal law.
• Commercially manufactured testosterone enanthate (brand and generic) is FDA-approved for male hypogonadism; compounded versions are not FDA-approved products, even where compounding itself is legal.
• Endocrine Society guidance recommends baseline and follow-up hematocrit and testosterone monitoring, with a stated action point if hematocrit becomes elevated.
• 503A compounding pharmacies may legally prepare patient-specific testosterone enanthate under a valid prescription; 503B facilities operate under a different, batch-production framework.
• Diagnosis of hypogonadism conventionally requires at least two morning total testosterone measurements below the reference threshold plus symptoms, per clinical guideline consensus.

Date-sensitive, verify before you rely on it

• Your specific AHCCCS or managed-care plan's current formulary status for testosterone enanthate.
• Your commercial insurer's current prior authorization criteria and copay tier for generic versus brand testosterone enanthate.
• Any specific cash price at a named pharmacy chain or compounding pharmacy.
• Current discount-card (GoodRx, SingleCare, RxSaver) pricing at a specific Arizona pharmacy.
• Whether your state's or a specific telehealth platform's controlled-substance prescribing rules currently require an in-person visit, since federal telehealth flexibilities for controlled substances have changed more than once in recent years.
• Whether a 340B-eligible clinic near you currently stocks and dispenses testosterone enanthate at 340B pricing.

If a number or rule you find elsewhere does not clearly state the date it was current, treat it as unverified.